Using benefit-based tailored treatment to improve the use of antihypertensive medications

Circulation

Volumn 128, Issue 21, 2013, Pages 2309-2317

  Sussman, Jeremy ^a,b   Vijan, Sandeep ^a,b   Hayward, Rod ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Epidemiology; Hypertension; Primary prevention; Treatment outcome

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; HYDROCHLOROTHIAZIDE; LISINOPRIL;

ADULT; AGED; ARTICLE; BENEFIT BASED TAILORED TREATMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; DRUG THERAPY; EFFECT SIZE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EPIDEMIOLOGY; HYPERTENSION; PRIMARY PREVENTION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MODELS, STATISTICAL; MYOCARDIAL INFARCTION; NUTRITION SURVEYS; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84888173755     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.002290     Document Type: Article

References (43)

1. Hayward RA, Kent DM, Vijan S, Hofer TP. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol. 2006;6:18.
2. Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: An open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes. 2012;5:2-5.
3. Sussman JB, Vijan S, Choi H, Hayward RA. Individual and population benefits of daily aspirin therapy: A proposal for personalizing national guidelines. Circ Cardiovasc Qual Outcomes. 2011;4:268-275.
4. Kent DM, Hayward RA, Griffith JL, Vijan S, Beshansky JR, Califf RM, Selker HP. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med. 2002;113:104-111.
5. Rothwell PM, Warlow CP. Prediction of benefit from carotid endarterectomy in individual patients: A risk-modelling study: European Carotid Surgery Trialists' Collaborative Group. Lancet. 1999;353:2105-2110.
6. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med. 2010;152:69-77.
7. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860.
8. Timbie JW, Hayward RA, Vijan S. Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Arch Intern Med. 2010;170:1037-1044.
9. Timbie JW, Hayward RA, Vijan S. Diminishing efficacy of combination therapy, response-heterogeneity, and treatment intolerance limit the attainability of tight risk factor control in patients with diabetes. Health Serv Res. 2010;45:437-456.
10. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560-2572.
11. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(suppl 5):v1-v52.
12. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121(pt 2):293-298.
13. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
14. Timbie JW, Hayward RA, Vijan S. Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Arch Intern Med. 2010;170:1037-1044.
15. Timbie JW, Hayward RA, Vijan S. Diminishing efficacy of combination therapy, response-heterogeneity, and treatment intolerance limit the attainability of tight risk factor control in patients with diabetes. Health Serv Res. 2010;45:437-456.
16. National Center for Health Statistics. Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994 public-use data files. http://www.cdc.gov/nchs/nhanes/nh3data.htm. Accessed October 8, 2013.
17. Gregg EW, Cheng YJ, Cadwell BL, Imperatore G, Williams DE, Flegal KM, Narayan KM, Williamson DF. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA. 2005;293:1868-1874.
18. Romero CX, Romero TE, Shlay JC, Ogden LG, Dabelea D. Changing trends in the prevalence and disparities of obesity and other cardiovascular disease risk factors in three racial/ethnic groups of USA adults. Adv Prev Med. 2012;2012:172423.
19. Cameron AC, Trivedi PK. Microeconometrics Using Stata. College Station, TX: Stata Press; 2009.
20. Powers BJ, Olsen MK, Smith VA, Woolson RF, Bosworth HB, Oddone EZ. Measuring blood pressure for decision making and quality reporting: Where and how many measures? Ann Intern Med. 2011;154:781-788, W-289-W-290.
21. Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513-1518.
22. Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med. 1999;159:1197-1204.
23. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication: A risk profile from the Framingham Heart Study. Circulation. 1997;96:44-49.
24. Echouffo-Tcheugui JB, Kengne AP. Risk models to predict chronic kidney disease and its progression: A systematic review. PLoS Med. 2012;9:e1001344.
25. Arias E. United States life tables, 2004. Natl Vital Stat Rep. 2007;56:1-39.
26. Heron M. Deaths: Leading causes for 2004. Natl Vital Stat Rep. 2007;56:1-95.
27. Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L. Comparing impact and costeffectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150:243-254.
28. Stern M, Williams K, Eddy D, Kahn R. Validation of prediction of diabetes by the Archimedes model and comparison with other predicting models. Diabetes Care. 2008;31:1670-1671.
29. Bell KJ, Hayen A, Macaskill P, Craig JC, Neal BC, Irwig L. Mixed models showed no need for initial response monitoring after starting antihypertensive therapy. J Clin Epidemiol. 2009;62:650-659.
30. Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women: A cost-utility analysis. Arch Intern Med. 2007;167:290-295.
31. Wu J, Kraja AT, Oberman A, Lewis CE, Ellison RC, Arnett DK, Heiss G, Lalouel JM, Turner ST, Hunt SC, Province MA, Rao DC. A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens. 2005;18:935-942.
32. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ. 2003;326:1427.
33. Gold MR. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
34. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet. 1998;351:1755-1762.
35. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: Blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med. 2003;138:593-602.
36. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
37. Eddy DM, Adler J, Patterson B, Lucas D, Smith KA, Morris M. Individualized guidelines: The potential for increasing quality and reducing costs. Ann Intern Med. 2011;154:627-634.
38. Niiranen TJ, Hänninen MR, Johansson J, Reunanen A, Jula AM. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: The Finn-Home study. Hypertension. 2010;55:1346-1351.
39. Blaha MJ, Budoff MJ, DeFilippis AP, Blankstein R, Rivera JJ, Agatston A, O'Leary DH, Lima J, Blumenthal RS, Nasir K. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: Implications for the JUPITER population from MESA, a population-based cohort study. Lancet. 2011;378:684-692.
40. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: A meta-analysis. JAMA. 2011;305:913-922.
41. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB 3rd, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV, Anderson JL; American College of Cardiology Foundation/American Heart Association Task Force. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354-e471.
42. Beard AJ, Hofer TP, Downs JR, Lucatorto M, Klamerus ML, Holleman R, Kerr EA; Diabetes Clinical Action Measures Workgroup. Assessing appropriateness of lipid management among patients with diabetes mellitus: Moving from target to treatment. Circ Cardiovasc Qual Outcomes. 2013;6:66-74.
43. Goldstein MK. Using health information technology to improve hypertension management. Curr Hypertens Rep. 2008;10:201-207.